Context

Founded in 1997 in Brussels, ASIT biotech is a clinical stage biopharmaceutical company focused on the development and future commercialization of effective immunotherapy drugs for the treatment of allergies through its ASIT+™ technology platform.

One billion people worldwide currently suffer from an allergy, and this could rise to over four billion patients who could be affected by 2050, offering huge market potential for this innovative company.

Currently testing products to help treat allergies against grass pollen (Phase III trial stage), the house dust mite and peanut allergies (respectively in Phase I and Phase II trials).

In order to continue research and development for new drugs as well as for corporate development, ASIT biotech required additional financing to fund an additional Phase III for its lead product in grass pollen and for its Phase I and Phase II trials for house dust mite allergy and for food allergies (peanut, cows milk…).

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies. ASIT biotech has a headcount of 26 staff members at its headquarters in Brussels and a laboratory in Liège, Belgium.

Discover ASIT biotech

Olivier Garnier

Investment Banking

Jean de Pracomtal

Investment Banking

Hervé Ronin

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center